Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sil-ling Pruis, Yunjoo Karris Jeon, Fiona Pearce, Bernard Yu-Hor Thong & Mohamed Ismail Abdul Aziz. (2020) Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. Journal of Medical Economics 23:8, pages 838-847.
Read now
Read now
Larysa Strilchuk, Federica Fogacci & Arrigo Fg Cicero. (2019) Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opinion on Drug Safety 18:4, pages 261-271.
Read now
Read now
Tristan Pascart & Pascal Richette. (2017) Current and future therapies for gout. Expert Opinion on Pharmacotherapy 18:12, pages 1201-1211.
Read now
Read now
Articles from other publishers (23)
Melanie B. Morillon, Alexander Nørup, Jasvinder A. Singh, Nicola Dalbeth, William J. Taylor, Martin A. Kennedy, Birthe Mette Pedersen, Rebecca Grainger, Peter Tugwell, Fernando Perez-Ruiz, Cesar Diaz-Torne, N. Lawrence Edwards, Beverley Shea, Torkell J. Ellingsen, Robin Christensen & Lisa K. Stamp. (2023) Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set. Seminars in Arthritis and Rheumatism 60, pages 152191.
Crossref
Crossref
Ritch te Kampe, Sabrina Mai Nielsen, Ioana Hotea, Caroline van Durme, Robin Christensen & Annelies Boonen. (2022) Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis. Seminars in Arthritis and Rheumatism 56, pages 152049.
Crossref
Crossref
Kirsty McDowell, Paul Welsh, Kieran F. Docherty, David A. Morrow, Pardeep S. Jhund, Rudolf A. de Boer, Eileen O'Meara, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Ann Hammarstedt, Anna Maria Langkilde, Mikaela Sjöstrand, Daniel Lindholm, Scott D. Solomon, Naveed Sattar, Marc S. Sabatine & John J.V. McMurray. (2022)
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in
DAPA‐HF
. European Journal of Heart Failure 24:6, pages 1066-1076.
Crossref
Crossref
Jose Paulo P. Lorenzo, Ma. Hanna Monica Z. Sollano, Evelyn O. Salido, Julie Li‐Yu, Sandra A. Tankeh‐Torres, Ida Ayu Ratih Wulansari Manuaba, Md Mujibur Rahman, Binoy J. Paul, Mo Yin Mok, Monika De Silva, Prasanta Padhan, Ai Lee Lim, Melvin Marcial, Jennifer Jeanne Vicera, Syed Atiqul Haq, Sami Salman, Chiranthi K. Liyanage, Helen I. Keen, Cheng Yew Kuang, James Cheng‐Chung Wei, Rakhma Yanti Hellmi, Charlie E. ChanJr.Jr. & Worawit Louthrenoo. (2021) 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. International Journal of Rheumatic Diseases 25:1, pages 7-20.
Crossref
Crossref
Siliang Zhang, Qiming Xie, Shuqing Xie, Jianwei Chen, Qingyue Deng, Ling Zhong, Jing Guo & Yuan Yu. (2021) The association between urate‐lowering therapies and treatment‐related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta‐analysis of randomized trials. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:9, pages 781-791.
Crossref
Crossref
Alexandra Charlton & Paul Anthony MacMullan. (2021) Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear. The Journal of Rheumatology 48:7, pages 965-966.
Crossref
Crossref
Linggen Gao, Bin Wang, Ying Pan, Yan Lu & Rui Cheng. (2021) Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis. Clinical Cardiology 44:7, pages 907-916.
Crossref
Crossref
Meida Fan, Jian Liu, Bingcheng Zhao, Xinyu Wu, Xuefeng Li, Jieruo Gu & Naomi Schlesinger. (2020) Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clinical Rheumatology 40:2, pages 683-692.
Crossref
Crossref
Chung-Ming Tu, Guo-Shiang Tseng & Cheng-Wei Liu. (2021) Serum Uric Acid may be Associated with Left Ventricular Diastolic Dysfunction in Military Individuals. Military Medicine 186:1-2, pages e104-e111.
Crossref
Crossref
Shan‐Shan Sun, Dong‐Hu Zhang, Yue Shi, Cheng‐Jiang Lin & Jian‐Yang Lin. (2020) Efficacy and safety of urate‐lowering treatments in patients with hyperuricemia: A comprehensive network meta‐analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 729-742.
Crossref
Crossref
Yu-Jiun Lin, Shiyng-Yu Lin, Chang-Hsien Lin, Sen-Te Wang & Shy-Shin Chang. (2020) Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology 39:5, pages 1633-1648.
Crossref
Crossref
Sarah Stewart, Amy Tallon, William J. Taylor, Angelo Gaffo & Nicola Dalbeth. (2020) How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. Seminars in Arthritis and Rheumatism 50:2, pages 303-313.
Crossref
Crossref
Cheng-Wei Liu, Wei-Cheng Chang, Chiao-Chin Lee, Wen-Yi Shau, Fu-Shun Hsu, Man-Ling Wang, Tsung-Chih Chen, Chiao Lo & Juey-Jen Hwang. (2019) The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases 29:10, pages 1011-1022.
Crossref
Crossref
TENNEILLE TANA & PETER VADAS. (2019)
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and
HLA-B*58:01
Genotype
. The Journal of Rheumatology 46:9, pages 1250-1251.
Crossref
Crossref
N Lawrence Edwards, Jasvinder A Singh, Orrin Troum, Anthony E Yeo & Peter E Lipsky. (2019) Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. Rheumatology 58:8, pages 1422-1431.
Crossref
Crossref
Ching-Yen Su, Li-Jiuan Shen, Song-Chou Hsieh, Lian-Yu Lin & Fang-Ju Lin. (2019) Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Mayo Clinic Proceedings 94:7, pages 1147-1157.
Crossref
Crossref
Thomas Bardin & Pascal Richette. (2019) The role of febuxostat in gout. Current Opinion in Rheumatology 31:2, pages 152-158.
Crossref
Crossref
John A. Cuenca, Javier Balda, Ana Palacio, Larry Young, Michael H. Pillinger & Leonardo Tamariz. (2019) Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis. International Journal of Rheumatology 2019, pages 1-10.
Crossref
Crossref
Andreas Jordan & Ursula Gresser. (2018) Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals 11:2, pages 51.
Crossref
Crossref
Heng Cheng, Dewen Yan, Xin Zuo, Junying Liu, Wenlan Liu & Youming Zhang. (2018) A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. Pharmacogenetics and Genomics 28:5, pages 117-124.
Crossref
Crossref
Tristan Pascart & Frédéric Lioté. (2018) Gout: state of the art after a decade of developments. Rheumatology.
Crossref
Crossref
Lisa K. Stamp, Melanie B. Morillon, William J. Taylor, Nicola Dalbeth, Jasvinder A. Singh, Marissa Lassere & Robin Christensen. (2018) Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. The Journal of Rheumatology 45:3, pages 419-424.
Crossref
Crossref
Shu Li, Hongxi Yang, Yanan Guo, Fengjiang Wei, Xilin Yang, Daiqing Li, Mingzhen Li, Weili Xu, Weidong Li, Li Sun, Ying Gao & Yaogang Wang. (2016) Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific Reports 6:1.
Crossref
Crossref